Mirum Pharmaceuticals, Inc. - common stock (MIRM)

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health, plummeted 1.9% on March 5, 2026, marking its sharpest single-day decline of the year. The sell-off, triggered by

Mirum (MIRM) Q4 2025 Earnings Call Transcript

Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision equipment becomes more valuable, but demand remains tied to export controls and capital spending cycles.

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

The drugmaker is doing nearly everything else right.

The future looks bright for this high-flying biotech stock.

Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage powerhouse in the rare liver disease sector. As of early 2026, the company stands as a beacon of growth in the biotechnology landscape, recently surpassing annual revenue targets and achieving [...]

Don't wait too long to make a decision on these three stocks.

Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains.

Not all of these predictions may come true. But at least a few of them will likely do so.

These predictions were easy.

Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.

Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on.

A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next.

Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout.